Roche to buy US biotech firm Seragon for up to $1.7 billion


Roche Holding AG said it would pay up to $1.725 billion (£1.01 billion) to buy Seragon Pharmaceuticals, a privately-held San Diego-based biotech company that researches breast cancer treatments. Roche has long dominated the field of breast cancer with drugs such as Herceptin and recently won approval for Kadcyla and Perjeta, two treatments for patients whose cancer cells contain increased amounts of the protein known as HER2. Seragon, which was spun out from Aragon Pharmaceuticals last year when it was bought by Johnson & Johnson, is focused on developing a new generation of oral medicines designed to better tackle hormone receptor-positive breast cancer, and potentially other cancers.

Read the source article at

About the Author

Leave a Reply